Myelosuppression is a toxicity-related limitation for aranoza dosage. The drug proved effective in the treatment of uterine sarcoma, cancer of the head and neck, breast, Hodgkin's disease and lymphosarcoma during stage II of clinical studies. Complete regression was reported in the treatment of melanoma (ca. 12%). Good results of chemoimmunotherapy should be expected in untreated patients as well as intraarterial infusions for local lesions of the extremities. Clinical trials of aranoza used in combined modalities of therapy in various sites continue.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents.
Melanoma Res
February 2017
Department of Experimental Diagnosis and Therapy of Tumors, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
The increasing incidence of melanoma makes this cancer an important public health problem. Therapeutic resistance is still a major obstacle to the therapy of patients with metastatic melanomas. The aim of this study was to develop the melanoma cell line resistant to DNA-alkylating agents and to elucidate the mechanisms involved in acquired drug resistance.
View Article and Find Full Text PDFHematological toxicity of four combined chemotherapy schemes--TAr, TPAr, EPAr, and IPAr--involving aranose (Ar), cisplatin (P), etoposide (E), irinotecan (I), and topotecan (T) in therapeutic regimes has been studied on healthy mice in comparison to the treatment with Ar in a high therapeutic dose. It is established that Ar alone induces early leucopenia, mostly as a result of lymphocytopenia followed by the absolute and relative neutrophilia; the TAr treatment leads to a moderate neutropenia; whereas the ternary combinations cause a moderate lymphocytopenia. A relatively high hematological toxicity among the ternary combinations was observed for TPAr.
View Article and Find Full Text PDFData are presented on evaluation of use of combinations of aranosa (Ar), irinotecan (I) and cisplatin (C) in treatment of Lewis lung carcinoma. The drugs were administered i.p.
View Article and Find Full Text PDFThe paper discusses the results of phase II clinical trials of chemotherapy regimens using newly-developed cytostatics for disseminated small cell lung cancer. Taxotere (docetaxel)/cisplatin and campto(irinotecan)/cisplatin were investigated as first-line treatment. Doxorubicin and vincristine in combinations with a novel antitumor cytostatic aranoza were studied for application as second-line treatment.
View Article and Find Full Text PDF[Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Vopr Onkol
July 2004
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Aranoza and dacarbazine (DTIC) monotherapy and in combinations with aranoza and interferon-alpha (IPHN-alpha) as well as DTIC and IPHN-alpha was given to 175 patients (89 males and 86 females, aged 23-78) with disseminated skin melanoma. The effectiveness of aranoza and DTIC monotherapy was practically identical. Total response to DTIC used in combination with IPHN-alpha increased insignificantly: 25.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!